Barra, S;
Primo, J;
Gonçalves, H;
Boveda, S;
Providência, R;
Grace, A;
(2022)
Is amiodarone still a reasonable therapeutic option for rhythm control in atrial fibrillation?
Revista Portuguesa de Cardiologia
, 41
(9)
pp. 783-789.
10.1016/j.repc.2021.03.019.
Preview |
Text
Barra RPC.pdf - Accepted Version Download (1MB) | Preview |
Abstract
Amiodarone is the most potent antiarrhythmic drug available and is commonly prescribed to treat and prevent not only life-threatening ventricular arrhythmias but also atrial fibrillation (AF). The latest European Society of Cardiology AF guidelines state that amiodarone is recommended for long-term rhythm control in all AF patients but that other antiarrhythmic drugs should be considered first whenever possible, due to its extracardiac toxicity. In patients without significant or with only minimal structural heart disease, amiodarone is not listed as a possibility in their therapeutic scheme. Still, amiodarone is widely and liberally used, and is the most prescribed antiarrhythmic drug for patients with AF despite its high toxicity profile. Non-cardiovascular death was more frequent with amiodarone treatment than with a rate control strategy in AFFIRM, while meta-analyses suggest an association between amiodarone use in patients without structural heart disease and increased non-cardiovascular mortality. Severe or even fatal outcomes due to amiodarone may occur years after treatment initiation and are often not acknowledged by the prescribing physician, who may no longer be following the patient. The lack of widely accepted diagnostic criteria and symptom definitions may lead to underestimation of the incidence of severe side effects and of its toxicity. Unlike the underestimated risk of toxicity with amiodarone, severe complications associated with catheter ablation are usually directly ascribed to the treatment even by non-medical personnel, possibly resulting in overestimation of risks. This brief review will address the issue of amiodarone overuse and the frequent underestimation of its toxicity, while suggesting scenarios in which its use is entirely reasonable, and compare it with catheter ablation.
| Type: | Article |
|---|---|
| Title: | Is amiodarone still a reasonable therapeutic option for rhythm control in atrial fibrillation? |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.repc.2021.03.019 |
| Publisher version: | https://doi.org/10.1016/j.repc.2021.03.019 |
| Language: | English |
| Additional information: | © 2022 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espana, ˜ S.L.U. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Keywords: | Amiodarone; Toxicity; Pulmonary toxicity; Mortality; Atrial fibrillation; Catheter ablation |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Health Informatics |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10185465 |
Archive Staff Only
 |
View Item |
